Table 2.
Univariate and multivariate analysis of variables on RFS in the entire cohort (n = 22).
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| 3-Year RFS Rate (95%CI) | p Value | HR (95%CI) | p Value | |
| TIGIT+/NK (%) | 0.014 | — | — | |
| ≤55.1 (n = 16) | 93.3% (61.3–99.0%) | |||
| >55.1 (n = 6) | 40.0% (5.2–75.3%) | |||
| TIGIT+/CD56bright NK (%) | 0.51 | |||
| ≤43.0 (n = 12) | 74.1% (39.1–90.9%) | |||
| >43.0 (n = 10) | 87.5% (38.7–98.1%) | |||
| TIGIT+/CD56dim NK (%) | 0.014 | 0.045 | ||
| ≤56.2 (n = 16) | 93.3% (61.3–99.0%) | 1.0 | ||
| >56.2 (n = 6) | 40.0% (5.2–75.3%) | 10.1 (1.0–98.2) | ||
| Age (year) | 0.51 | |||
| <40 (n = 14) | 74.1% (39.1–90.9%) | |||
| ≥40 (n = 8) | 87.5% (38.7–98.1%) | |||
| Gender | 0.76 | |||
| Male (n = 8) | 75.0% (31.5–93.1%) | |||
| Female (n = 14) | 83.3% (48.2–95.6%) | |||
| WBC counts (×109/L) | 0.28 | |||
| ≤10.0 (n = 11) | 90.0% (47.3–98.5%) | |||
| >10.0 (n = 11) | 68.6% (30.5–88.7%) | |||
| Hemoglobin (g/L) | 0.41 | |||
| ≤76.0 (n = 10) | 88.9% (43.3–98.4%) | |||
| >76.0 (n = 12) | 71.6% (35.0–89.9%) | |||
| Platelet counts (×109/L) | 0.30 | |||
| ≤27.0 (n = 11) | 90.0% (47.3–98.5%) | |||
| >27.0 (n = 11) | 70.0% (32.9–89.2%) | |||
| BM blast percentage (%) | 0.18 | |||
| ≤55.0 (n = 13) | 90.9% (50.8–98.7%) | |||
| >55.0 (n = 9) | 64.8% (25.3–87.2%) | |||
| KIT mutation | 0.25 | |||
| Negative (n = 12) | 70.0% (32.9–89.2%) | |||
| Positive (n = 10) | 88.9% (43.3–98.4%) | |||
| Consolidation regimen | 0.054 | — | 0.15 | |
| Chemotherapy only (n = 12) | 63.6% (29.7–84.5%) | |||
| Allo-HSCT (n = 10) | 100.0% | |||
| CR after 1-course induction | 0.15 | |||
| No (n = 3) | 50.0% (0.60–91.0%) | |||
| Yes (n = 19) | 83.0% (55.9–94.2%) | |||
Bold text refers to the variables with p < 0.05.